EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

Amy Hirsch Shumaker, Adarsh Bhimraj iD, Roger Bedimo iD, Vincent Chi-Chung Cheng, Kara W Chew, Eric S Daar, David V Glidden iD, Robert W Shafer, Phyllis C Tien, Lindsey R Baden, Kelly Cawcutt, Kathleen Chiotos iD und 19 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf680 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Amy Hirsch Shumaker und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Infectious Diseases Society of America, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentHumansAdenosine MonophosphateAlanineCOVID-19SARS-CoV-2RitonavirAdultProlineHydroxylaminesCytidine

Stichwörter der Autor:innen

COVID-19guidelinemolnupiravirnirmatrelvir/ritonavirremdesivir

Substanzen

Antiviral AgentsremdesivirAdenosine MonophosphateAlanineRitonavirmolnupiravirProlineHydroxylaminesCytidine

Autor:innen und Institutionen

  • Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
  • Department of Medicine, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
  • Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Medicine, UT Southwestern/VA North Texas Health Care System, Dallas, Texas, USA.
  • Department of Microbiology, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
  • Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Adarsh Bhimraj, Roger Bedimo, David V Glidden, Kathleen Chiotos, Laura Riley, Shmuel Shoham, Pablo Tebas, Zachary Willis, Joshua Wolf

Förderung

  • Infectious Diseases Society of America
  • NCI NIH HHS
  • NIH HHS
  • HHS
  • National Cancer Institute
  • National Institutes of Health
  • Department of Health and Human Services

Zitieren

APA

Shumaker, A. H., Bhimraj, A., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Shafer, R. W., Tien, P. C., Baden, L. R., Cawcutt, K., Chiotos, K., Dzierba, A. L., Hardy, E. J., Johnson, S., Kim, A. Y., MacBrayne, C., Martin, G. S., Nadig, N., …, & Gandhi, R. T. (2026). 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf680

Vancouver

Shumaker AH, Bhimraj A, Bedimo R, Cheng VC, Chew KW, Daar ES, et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf680

BibTeX
@article{Shumaker2026,
  author = {Shumaker, Amy Hirsch and Bhimraj, Adarsh and Bedimo, Roger and Cheng, Vincent Chi-Chung and Chew, Kara W and Daar, Eric S and Glidden, David V and Shafer, Robert W and Tien, Phyllis C and Baden, Lindsey R and Cawcutt, Kelly and Chiotos, Kathleen and Dzierba, Amy L and Hardy, Erica J and Johnson, Steven and Kim, Arthur Y and MacBrayne, Christine and Martin, Greg S and Nadig, Nandita and Nakamura, Mari M and Oliveira, Carlos R and Pearson, Jeffrey C and Riley, Laura and Shoham, Shmuel and Tebas, Pablo and Willis, Zachary and Wolf, Joshua and Loveless, Jennifer and Morgan, Rebecca L and Falck-Ytter, Yngve and Gandhi, Rajesh T},
  title = {2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf680}
}
Kostenlos starten →